An international team of researchers has provided a genetic diagnosis for 30 individuals whose condition was undiagnosed for years despite extensive ...

GTX-102 has been granted Orphan Drug Designation, Rare Pediatric Disease Designation, and Fast Track Designation from the FDA and Orphan Designation and PRIME designation from the EMA. About the Phase ...

Cash, cash equivalents, and marketable securities of $360.1 million at Q3 2024 - CARLSBAD, Calif., Nov. 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical ...

German pharma major Bayer’s independently operated subsidiary Asklepios BioPharmaceutical (AskBio) today announced that AB-1003 (also known as LION-101) has received rare pediatric disease designation ...

Given the rare pediatric orphan disease designation and the lack of any approved therapy for ATRT, we are particularly enthusiastic of the clinical studies in ATRT and are in active discussions with ...

(AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that AB-1003 (also known as LION-101) has received rare pediatric disease ...

Pharmaceuticals announced that the United States FDA granted Orphan Drug Designation and Rare Pediatric Disease Designation ...

AGOURA HILLS, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its presentation at SITC 2024. Dr. Cynthia Lee, VP of R&D will be presenting Sapu Bio ...

Acadia Pharmaceuticals has bagged $150 million from the sale of a priority review voucher (PRV)—although the biotech will ...

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

The FDA approved zolbetuximab (Vyloy) on October 18, 2024, as a first-line treatment for locally advanced unresectable or ...